better fear guidanc remain suspend medsurg
continu offer reliabl diversif away elect surgeri
trim pt
maintain buy rate trim pt
one compani pre-announc prelim revenue
investor worri elect procedur exposur would hamper result
divers portfolio help off-set procedur declin late march came
ahead covid adjust estimate revenue beat estimate organ
growth y/i inclus extra sell day benefit driven resili
knee instrument medic even spine extent ep vs
pandem adjust estim favor tax see robust demand
specif segment bed stretcher physio emerg cot
preview recoveri like gradual deferr
procedur base longer origin assum revenue capit
small high-dollar though defer share
recov recent low think investor longer invest
horizon continu view reliabl less elect evidenc today
result even guidanc remain suspend current valuat remain peer
histor rel average keep share attract view
expect procedur recoup meaning come quarter
signific demand capit equip hospit posit treat covid
patient capit portfolio made sale large-
small-capit equip contribut respect small-capit
use track in-lin procedur large-capit bed
experienc heighten demand difficult ascertain whether
demand pulled-forward management note strength demand long way
top stockpil management see opportun outfit asc -- boom light
oper tabl mako capit power tool etc -- procedur shift
come back set first
global slowdown march steepen april ou geographi
experienc earlier downturn show green shoot last week march
total sale fell april management expect declin reach y/
to-dat april europ sale management expect declin
continu throughout us orthoped spine sale
medsurg neurotechnolog sale declin howev constant-
currenc organ basi us orthoped sale march acceler
adopt cementless knee mako worst mako order
delay order cancel
price pressur more-mut shift busi mix dynam price
pressur unchang underli basi product mix shift eas
price headwind near-term like remain intact
elect procedur reemerg revert price back normal rate
valuat rate buy base estim
month ep estim risk discuss
factset btig estim compani
document million except per share amount
collect across divis shown abil grow organ revenu consist multipl broader
medic technolog market believ diversifi revenu composit consist execut combin
lead posit orthoped robot made name long-term one investor reli
encourag return time total return result compound-annual-growth-rate well ps
even premium valuat expens respect execut believ worth own
lap approv mako tka japan
lap acquisit mobiu imag carden robot
potenti closur acquisit
expect ramp camera sale within endoscopi
expect gain neurovascular aspir portfolio
base case scenario call organ revenu growth flat
result pandem impact revenu ep estim
guidanc remain suspend given limit visibl result pandem
upsid base case scenario come sever front better
expect integr legaci spine greater expect mako
placement util well faster expect growth endoscopi
neurotechnolog new product line rapid realiz
margin gain ctg could acceler ep growth also believ improv
recoveri elect procedur could lift share faster
slower expect integr deceler mako util
competit system enter market weaker expect capit
environ would drag share slowdown elect procedur china
could also drag share
one world lead
innov product servic
orthopaed medic surgic
neurotechnolog spine help
improv patient hospit outcom
report result overal revenu came y/i covid adjust estim
report consensu y/i note mani estim adjust organ
revenu growth came y/i
segment report orthopaed revenu y/i covid adjust estim
y/i medsurg revenu y/i covid-adjust estim y/i
neurotechnolog spine revenu came y/i in-lin covid adjust estim
y/i spine perform better assum off-set neurotech weak result suppli disrupt
adj gross margin estim percentag revenu adj sg
estim estim adj ebit margin
estim told adj ep beat adjust estim
btig research estim compani file
made follow chang model
revenu side follow management commentari regard april trend model reduct revenu
previous assum lower reduct increa expect similarli assum faster
recoveri management caution gradual recoveri lower ramp expect bolu
lesser extent reduc recoveri expect gradual improv primarili within us
 believ neg impact lower revenu higher margin product see less product
convers management reduc sg result cost mitig strategi like remain intact
increas incom interest line guid management guidanc remain suspend
btig research estim compani file
sale
cog revenu
sg revenu
 revenu
btig research estim compani report
domest sale
sale
btig research estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
